Medicinsk behandling af tidlig brystkræft

Christina Annette Bjerre*, Jeanette Dupont Rønlev, Ann Søegaard Knop

*Corresponding author af dette arbejde

Abstract

Adjuvant and neoadjuvant therapy of early breast cancer reduces the risk of relapse and breast cancer mortality. Treatment modalities include chemotherapy, endocrine therapy, human epidermal growth factor receptor 2-targeted agents, bisphosphonates, immunotherapy, cyclin-dependent kinase inhibitors 4/6- and poly-ADP-ribose polymerase inhibitors. All cases are reviewed at multidisciplinary breast cancer tumour boards. An individualized risk stratification model is applied in this review to optimize the risk-benefit ratio for each patient, and shared decision-making is an integrated part of (neo)adjuvant therapy. Danish guidelines for breast cancer treatment are available at Danish Breast Cancer Cooperative Group's home page.

Bidragets oversatte titelMedical treatment of early breast cancer
OriginalsprogDansk
ArtikelnummerV02230095
TidsskriftUgeskrift for Laeger
Vol/bind186
Udgave nummer12
ISSN0041-5782
DOI
StatusUdgivet - 18 mar. 2024

Emneord

  • Humans
  • Female
  • Breast Neoplasms/pathology
  • Neoplasm Recurrence, Local/drug therapy
  • Antineoplastic Agents/therapeutic use
  • Combined Modality Therapy
  • Immunotherapy

Fingeraftryk

Dyk ned i forskningsemnerne om 'Medicinsk behandling af tidlig brystkræft'. Sammen danner de et unikt fingeraftryk.

Citationsformater